DarioHealth Corp. (DRIO) Earns News Sentiment Score of 0.23
Media headlines about DarioHealth Corp. (NASDAQ:DRIO) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DarioHealth Corp. earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.1129177624281 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Should You Sell DarioHealth Corp (DRIO) For This Reason? (finance.yahoo.com)
- DarioHealth’s CEO and MyDario to Appear on The Dr. Oz Show (finance.yahoo.com)
- DarioHealth’s MyDario to Appear on The Dr. Oz Show (finance.yahoo.com)
- DarioHealth Launches into the German Diabetes Market (finance.yahoo.com)
Separately, Aegis assumed coverage on shares of DarioHealth Corp. in a research report on Tuesday, August 29th. They set a “buy” rating and a $3.50 price objective for the company.
DarioHealth Corp. (NASDAQ DRIO) traded up 1.06% during trading on Friday, hitting $1.92. 8,492 shares of the company were exchanged. DarioHealth Corp. has a 12 month low of $1.69 and a 12 month high of $4.63. The company’s market capitalization is $18.73 million. The company has a 50-day moving average of $1.82 and a 200-day moving average of $1.82.
DarioHealth Corp. (NASDAQ:DRIO) last released its earnings results on Monday, August 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.13). DarioHealth Corp. had a negative net margin of 206.95% and a negative return on equity of 626.32%. The company had revenue of $1.21 million during the quarter. Analysts forecast that DarioHealth Corp. will post ($0.62) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/08/dariohealth-corp-drio-earns-news-sentiment-score-of-0-23.html.
About DarioHealth Corp.
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
Receive News & Stock Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related stocks with our FREE daily email newsletter.